Key Points
- Joana Goncalves sold 7,000 ORKA shares on Feb 17 at an average price of $32.37 for $226,590, trimming her holding by 17.07% to 34,018 shares (≈$1.10M).
- That sale follows two prior monthly disposals of 7,000 shares each on Jan 15 ($31.81) and Dec 19 ($30.61), totaling 21,000 shares sold over three months.
- Despite the insider selling, institutions own 56.44% of ORKA with several large new stakes (e.g., Viking, Paradigm, Remedium, Avoro, Deep Track), and analysts have a consensus "Moderate Buy" with an average target of $54.50.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the business's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the sale, the insider directly owned 34,018 shares of the company's stock, valued at approximately $1,101,162.66. The trade was a 17.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Joana Goncalves also recently made the following trade(s):
- On Thursday, January 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $31.81, for a total transaction of $222,670.00.
- On Friday, December 19th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $30.61, for a total transaction of $214,270.00.
Oruka Therapeutics Stock Up 1.5%
ORKA opened at $32.68 on Wednesday. The company has a market cap of $1.58 billion, a PE ratio of -17.20 and a beta of -0.38. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $36.51. The company has a 50-day moving average price of $31.64 and a 200 day moving average price of $25.22.
Hedge Funds Weigh In On Oruka Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Viking Global Investors LP purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at $51,280,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Oruka Therapeutics during the 4th quarter valued at about $51,840,000. Remedium Capital Partners LLC purchased a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $47,054,000. Avoro Capital Advisors LLC purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at about $25,640,000. Finally, Deep Track Capital LP increased its position in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock worth $51,051,000 after purchasing an additional 735,983 shares during the last quarter. Institutional investors and hedge funds own 56.44% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on ORKA shares. HC Wainwright lowered their price target on Oruka Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, October 27th. Guggenheim assumed coverage on Oruka Therapeutics in a report on Monday, October 27th. They issued a "buy" rating and a $60.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research note on Thursday, November 13th. They set a "buy" rating and a $45.00 target price on the stock. BTIG Research upped their target price on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, January 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Oruka Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $54.50.
Check Out Our Latest Stock Report on Oruka Therapeutics
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
